Part of a Trump administration rule that targets the drug rebate system is delayed until 2023, the Department of Health and Human Services announced Thursday.
The notice about this portion of the drug rebate rule (0936-AA08) comes after a pharmacy liaison group successfully argued in court it would significantly disrupt negotiations with drugmakers.
The delayed portion of the rule would strip legal protections for payment systems that depend on a drug’s list price. The Pharmaceutical Care Management Association asked the court to void the 2022 effective date because it says the HHS rushed the process and failed to coordinate with ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.